|
Effect of dapagliflozin on renal function and glucose and lipid metabolism in patients with type 2 diabetes mellitus
Ji Gaode, Jiang Lihua, Li Qun
International Medicine and Health Guidance News
2022, 28 (11):
1579-1583.
DOI: 10.3760/cma.j.issn.1007-1245.2022.11.023
Objective To observe the effect of dapagliflozin on renal function and glucose and lipid metabolism in patients with type 2 diabetes mellitus (T2DM).
Methods This was a prospective study.
Eighty-six patients with T2DM admitted to Jinan Second People's Hospital from July 2019 to July 2021 were selected as the research objects. They were divided into a control group and an observation group by the random number table method, with 43 cases in each group. The control group had 25 males and 18 females, and they were (52.80±5.77)years old. The obser vation group had 28 males and 15 females, and they were (53.19±5.82)years old, All the patients were given conventional treatment, and the observation group were treated with dapagliflozin on this basis. The clinical effects, the levels of blood glucose [fasting blood glucose (FBG), 2h postprandial blood glucose (2hPG), and glycosylated hemoglobin (HbA
1c)], blood lipids [total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C)], oxidative stress indicators [malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px)], and renal function indicators [blood urea nitrogen (BUN), serum creatinine (Scr), and urine microalbumin (UMA)], and the incidences of adverse reactions were compared between these two groups. The independent-sample
t test, paired
t test, and
χ
2 test were applied.
Results The treatment response rate in the observation group was higher than that in the control group [93.02% (40/43) vs. 74.42% (32/43)], with a statistical difference (
χ2=5.161,
P=0.023). After the treatment, the levels of FBG, 2hPG, HbA
1c, TC, TG, LDL-C, MDA, BUN, Scr, and UMA were (6.50±1.33) mmol/L, (8.35±1.44) mmol/L, (6.01±0.54)%, (4.58±0.23) mmol/L, (1.41±0.22) mmol/L, (2.23±0.34) mmol/L, (3.20±0.33) μmol/L, (6.33±1.07) mmol/L, (110.53±18.77) μmol/L, and (10.34±3.21) mg/L in the observation group, which were significantly lower than those in the control group [(7.39±1.50) mmol/L, (11.29±2.53) mmol/L, (7.02±1.19)%, (5.23±0.70) mmol/L, (1.95±0.44) mmol/L, (3.31±0.52) mmol/ L, (4.50±0.52) μmol/L, (9.86±2.55) mmol/L, (178.41±25.36) μmol/L, and (18.55±5.27) mg/L], with statistical differences (
t=2.911, 6.623, 5.068, 5.785, 7.198, 11.399, 13.842, 8.371, 14.108, and 8.725; all
P<0.05). The levels of HDL-C and SOD were (1.74±0.65) mmol/L and (43.96±8.22) U/ml in the observation group, which were significantly higher than those in control group [(1.46±0.53) mmol/L and (36.77±7.03) U/ml], with statistical differences (
t=2.189 and 4.359; both
P<0.05). There was no statistical difference in GSH-Px between the two groups (
t=0.206,
P=0.837). There was no statistical difference in the incidence of adverse reactions between the two groups [4.65% (2/43) vs. 9.30% (4/43);
χ2=0.677,
P=0.410].
Conclusion Dapagliflozin is effective in the treatment of T2DM, and can effectively control blood glucose level and improve lipid metabolism, oxidative stress, and renal function.
Reference |
Related Articles |
Metrics
|
|